Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus Price Target from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given an average rating of “Hold” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $3.75.

A number of equities analysts recently commented on HOWL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64. Following the completion of the transaction, the director directly owned 1,785,687 shares of the company’s stock, valued at approximately $1,285,694.64. The trade was a 8.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 581,111 shares of company stock worth $417,052. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares during the period. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $409,000. Finally, Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the 3rd quarter worth about $304,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Trading Up 9.7%

Shares of NASDAQ:HOWL opened at $0.68 on Friday. Werewolf Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.38. The company has a 50-day moving average price of $0.81 and a 200 day moving average price of $0.85. The company has a market cap of $33.05 million, a price-to-earnings ratio of -0.55 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, equities analysts forecast that Werewolf Therapeutics will post -1.29 EPS for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.